Skip to content
★ Sign in to follow
BioInvent International Aktiebolag logo

BioInvent International Aktiebolag Stock: price and insider trades · Sweden

ISIN SE0000789711SE·Mcap SEK 1.4BHealth Care

No insider purchase over the last 90 days. The latest, by Leonard Kruimer, was filed 18 Jul 2023.

BioInvent International Aktiebolag: what insiders have been doing

This page follows insider dealings at BioInvent International Aktiebolag as filed with Finansinspektionen, a company from the Health Care sector. Between 22 October 2025 and 22 October 2026, 1 insider published 2 filings.

None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.

Insider buying of BioInvent International Aktiebolag has been absent for the past year.

Compared with its exchange (882 companies, median 8 filings), a count of 2 filings is below the norm. The full history, which starts in 2023, counts 2 purchases against no sales.

This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.

Insider Decl.
6
Thresholds
n/a
Buy Volume
€26,592
2 ops. · all time
Sell Volume
n/a
n/a

Since the insiders bought

  • Filed 18 Jul 2023 · 1209 days ago · €16k
    +146.0%
    Entry SEK 17.62 · Close at T+365 SEK 43.35

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Financial data

as of FY 2025

FY ended December 2025 · cache

SEK 21.60
Analyst consensus
3 analysts
1.33/5
SEK 65.00Target SEK 76.57(+254%)SEK 90.00
Income statement
RevenueSEK 226.5M
EBITDA-SEK 312.2M-138% margin
Net income-SEK 332.9M-147.0% margin
Valuation
PER (forward)-3.0x
P/Book4.5x
Beta-0.06
Balance sheet & cash
Market capSEK 1.4B
Total debtSEK 8.5M
Free Cash Flow-SEK 255M
Debt / Equity7%
Profitability & ownership
ROE-88.1%
ROA-47.5%
% insiders10.2%
% institutions57.8%
Last declaration on 29 May 2026
Declarations6 total
  • ●
    Ekonomichef/finanschef/finansdirektörExecutives
    0FI-SE
    980,200 shares0TeckningsoptionFI:csv-a939129c9160197fb57e
  • ●
    Ekonomichef/finanschef/finansdirektörExecutives
    0FI-SE
    980,200 shares0TeckningsoptionFI:A003Z320-1
  • ●
    Ekonomichef/finanschef/finansdirektörExecutives
    0FI-SE
    1,032,400 shares0TeckningsoptionFI:csv-1cb5d7b7eaceb7797e82
  • ▲
    StyrelseordförandeExecutives
    180,000 SEK13FI-SE
    10,000 shares@ SEK 18.0058.8% of flowAktieISIN SE0000789711FI:csv-6b3873cc4c8eeedeb266
    Canonical exit: 15 Oct 2023 (T+90)
  • ●
    Ekonomichef/finanschef/finansdirektörExecutives
    0FI-SE
    948,300 shares0TeckningsoptionFI:csv-c7ded3019ba6772b2503
  • ▲
    StyrelseordförandeExecutives
    127,250 SEK11FI-SE
    5,000 shares@ SEK 25.4541.2% of flowAktieISIN SE0000789711FI:csv-7448348c2775b8aecc33
    Canonical exit: 23 Aug 2023 (T+90)

6 of 6 declarations

About BioInvent International Aktiebolag

BioInvent International Aktiebolag is a Swedish biopharmaceutical company focused on developing treatments for cancer. It is listed on the Stockholm Stock Exchange under the symbol XSTO.